CRISPR Therapeutics (CRSP) Tops Q2 EPS by 115c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.98), $1.15 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• Arrive AI and DXC Technology partner to bring delivery tech to factories